دورية أكاديمية
COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients
| العنوان: | COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients |
|---|---|
| المؤلفون: | Mary J. Kasten, Brian D. Lahr, Anusha Parisapogu, Zachary A. Yetmar, John C. O’Horo, Robert Orenstein, Pablo Moreno Franco, Raymund R. Razonable, Paschalis Vergidis, Aditya S. Shah, Mark J. Enzler, David J. Inwards, Philippe R. Bauer |
| المصدر: | Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023) |
| بيانات النشر: | Nature Portfolio, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Medicine LCC:Science |
| مصطلحات موضوعية: | Medicine, Science |
| الوصف: | Abstract The role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma in the treatment of Coronavirus Disease 2019 (COVID-19) in immunosuppressed individuals remains controversial. We describe the course of COVID-19 in patients who had received anti-CD20 therapy within the 3 years prior to infection. We compared outcomes between those treated with and those not treated with high titer SARS-CoV2 convalescent plasma. We identified 144 adults treated at Mayo clinic sites who had received anti-CD20 therapies within a median of 5.9 months prior to the COVID-19 index date. About one-third (34.7%) were hospitalized within 14 days and nearly half (47.9%) within 90 days. COVID-19 directed therapy included anti-spike monoclonal antibodies (n = 30, 20.8%), and, among those hospitalized within 14 days (n = 50), remdesivir (n = 45, 90.0%), glucocorticoids (n = 36, 72.0%) and convalescent plasma (n = 24, 48.0%). The duration from receipt of last dose of anti-CD20 therapy did not correlate with outcomes. The overall 90-day mortality rate was 14.7%. Administration of convalescent plasma within 14 days of the COVID-19 diagnosis was not significantly associated with any study outcome. Further study of COVID-19 in CD20-depleted individuals is needed focusing on the early administration of new and potentially combination antiviral agents, associated or not with vaccine-boosted convalescent plasma. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2045-2322 |
| Relation: | https://doaj.org/toc/2045-2322 |
| DOI: | 10.1038/s41598-023-48145-x |
| URL الوصول: | https://doaj.org/article/ee7820fcb8f14da9b1b2aedca63c51e8 |
| رقم الأكسشن: | edsdoj.7820fcb8f14da9b1b2aedca63c51e8 |
| قاعدة البيانات: | Directory of Open Access Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 20452322 |
|---|---|
| DOI: | 10.1038/s41598-023-48145-x |